Modalis Therapeutics Corporation (JP:4883)
:4883
Want to see JP:4883 full AI Analyst Report?
4883 Stock Chart & Stats
¥56.00
-¥3.00(-2.91%)
At close: 4:00 PM EST
¥56.00
-¥3.00(-2.91%)
Day’s Range― - ―
52-Week Range¥33.00 - ¥103.00
Previous CloseN/A
Volume5.80M
Average Volume (3M)719.68K
Market Cap
¥3.18B
Enterprise Value¥1.52B
Total Cash (Recent Filing)¥3.26B
Total Debt (Recent Filing)¥0.00
Price to Earnings (P/E)―
Beta>-0.01
Next Earnings
Aug 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-24.01
Shares Outstanding96,334,100
10 Day Avg. Volume617,120
30 Day Avg. Volume719,680
Financial Highlights & Ratios
PEG Ratio0.81
Price to Book (P/B)1.55
Price to Sales (P/S)0.00
P/FCF Ratio-2.04
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-22.2
Revenue Forecast (FY)¥800.00M
Bulls Say, Bears Say
Bulls Say
Focused R&D PlatformModalis’ explicit focus on gene expression–modulating therapies creates a clear, durable scientific niche. A concentrated platform can generate proprietary assets, higher entry barriers, and targeted programs for genetic diseases, improving long-term commercial optionality if clinical success follows.
Conservative Reported LeverageReported absence of debt in recent years lowers near-term bankruptcy and interest burden risk. For a cash-burning developer, low leverage preserves strategic flexibility to raise equity or partner on program funding without fixed debt servicing constraints, supporting survivability across cycles.
Lean Organizational StructureA very small headcount implies a low fixed-cost base and capital-efficient operating model typical of early-stage biotech. This lean structure supports nimble program prioritization, reduced overhead, and the ability to allocate limited cash to core R&D activities, extending runway relative to larger peers.
Bears Say
Zero Revenue And Recurring LossesSustained absence of revenue means the firm is wholly reliant on future trial outcomes and external financing for value creation. Large recurring net losses consume equity and reduce optionality; absent demonstrable commercial products, the firm's long-term viability hinges on successful clinical or partnering milestones.
Persistent Negative Cash FlowConsistent negative operating and free cash flow indicates ongoing cash burn and funding dependence. This structural outflow elevates liquidity and dilution risk, constrains ability to advance multiple programs, and makes strategic choices dependent on external capital availability and terms over the medium term.
Erosion Of Shareholders' EquityMeaningful erosion of shareholders' equity over several years reduces the balance-sheet buffer against future losses and limits borrowing or partnering leverage. Continued equity decline signals cumulative negative returns and raises structural financing risk for late-stage program investment or unexpected setbacks.
Modalis Therapeutics Corporation News
4883 FAQ
What was Modalis Therapeutics Corporation’s price range in the past 12 months?
Modalis Therapeutics Corporation lowest stock price was ¥33.00 and its highest was ¥103.00 in the past 12 months.
What is Modalis Therapeutics Corporation’s market cap?
Modalis Therapeutics Corporation’s market cap is ¥3.18B.
When is Modalis Therapeutics Corporation’s upcoming earnings report date?
Modalis Therapeutics Corporation’s upcoming earnings report date is Aug 12, 2026 which is in 61 days.
How were Modalis Therapeutics Corporation’s earnings last quarter?
Modalis Therapeutics Corporation released its earnings results on May 14, 2026. The company reported -¥3.64 earnings per share for the quarter, missing the consensus estimate of N/A by -¥3.64.
Is Modalis Therapeutics Corporation overvalued?
According to Wall Street analysts Modalis Therapeutics Corporation’s price is currently Overvalued.
Does Modalis Therapeutics Corporation pay dividends?
Modalis Therapeutics Corporation does not currently pay dividends.
What is Modalis Therapeutics Corporation’s EPS estimate?
Modalis Therapeutics Corporation’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Modalis Therapeutics Corporation have?
Modalis Therapeutics Corporation has 96,334,100 shares outstanding.
What happened to Modalis Therapeutics Corporation’s price movement after its last earnings report?
Modalis Therapeutics Corporation reported an EPS of -¥3.64 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 3.03%.
Which hedge fund is a major shareholder of Modalis Therapeutics Corporation?
Currently, no hedge funds are holding shares in JP:4883
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Modalis Therapeutics Corporation
Modalis Therapeutics Corporation focuses on discovering and developing treatments for severe genetic conditions. The company utilizes its proprietary CRISPR-GNDM technology to create therapies by controlling gene expression through the epigenetic modulation of specific genetic loci. Modalis also has a collaborative research agreement with JCR Pharmaceuticals Co., Ltd., aimed at assessing gene therapy drug delivery methods for the central nervous system (CNS), particularly for CNS-related disorders. Founded in 2016, the company was initially known as EdiGENE Corporation before changing its name to Modalis Therapeutics Corporation in August 2019. Its operations are based in Tokyo, Japan.
Technical Analysis
Solasia Pharma KK
―
Nippon Chemiphar Co., Ltd.
―
Taiko Pharmaceutical Co., Ltd.
―
Symbio Pharmaceuticals Limited
―
Cyfuse Biomedical K.K.
―